CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

SARS-CoV-2 infects the ACE2-expressing ciliated cells, replicates, and then infects the neighboring cells upon apical release, which occurs within six hours from the initial infection.

Since the start of the SARS-CoV-2 pandemic, several variants of the virus have developed into Variants of Concern (VOCs), as ...

In the SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) study, which involved a large cohort of asymptomatic health care workers who underwent polymerase-chain-reaction (PCR) testing every 2 ...

SARS-CoV-2 ribonucleic acid was present at 84 anatomical sites in significantly greater amounts among respiratory tissues than other tissues. SARS-CoV-2 RNA levels among early cases, mid-cases ...

The SARS-CoV-2 genome consists of nearly 30,000 RNA bases. Scientists have identified several regions known to encode protein-coding genes, based on their similarity to protein-coding genes found ...

Since the start of the COVID-19 pandemic, there has been controversy surrounding the origins of SARS-CoV-2. New research from the University of California, San Diego (UCSD), School of Medicine ...

Disparate temperature-dependent virus–host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium. PLOS Biology, 2021; 19 (3): e3001158 DOI: 10.1371/journal.pbio.3001158 ...

In this article, the authors discuss the challenges of SARS-CoV-2 infection in patients with a weakened immune system, including the potential implications regarding viral evolution and transmission.

UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...